Lumipulse G pTau181
Alzheimer's Disease Diagnosis
LaunchedCommercial (CE Mark)
Key Facts
Indication
Alzheimer's Disease Diagnosis
Phase
Launched
Status
Commercial (CE Mark)
Company
About H.U. Group Holdings
H.U. Group Holdings is a leading integrated healthcare company in Japan, with a core business in clinical laboratory testing and the development, manufacturing, and sale of in-vitro diagnostics. Its strategic subsidiaries, SRL and Fujirebio, provide a comprehensive portfolio from routine testing to advanced cancer diagnostics and companion diagnostics. The company leverages its dual strength in testing services and IVD manufacturing to drive growth in precision medicine and global diagnostics markets.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Diagnosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Lumipulse G β-Amyloid Ratio (1-42/1-40) | H.U. Group Holdings | Approved |